Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Platelet Transfusion Refractoriness
NCT02298933Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Countries
- 1
- Sponsor
- National Heart, Lung, and Blood Institute
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Drugs
- eculizumab
- Conditions
- alloimmune platelet refractoriness
01
Overview
Phase 2, open-label trial of eculizumab in alloimmune platelet refractoriness, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Subjects With Sustained Platelet Transfusion Responsiveness at 24 hours. Started Nov 2014; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adults with thrombocytopenia and alloimmune platelet refractoriness characterized by HLA antibodies and low corrected count increments (CCI) after transfusions.
04
Endpoints
Primary
Number of Subjects With Sustained Platelet Transfusion Responsiveness
Beyond the preview
Go deeper on NCT02298933.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298933.